SEC Form 4 · accession 0001237899-18-000014
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
P Roy Vagelos
Officer — Chairman of the Board · Director
Period of report
Aug 20, 2018
Accepted (ET)
Aug 21, 2018 · 4:55 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 20, 2018 | M | 210 | $21.25 | A | 400,057 | D | |
| Common Stock | Aug 20, 2018 | F | 108 | $374.46 | D | 399,949 | D | |
| Common Stock | holding | — | — | — | 2,310 | I | By 401(k) Plan | |
| Common Stock | holding | — | — | — | 147,934 | I | by CLAT | |
| Common Stock | holding | — | — | — | 83,652 | I | by Spouse as Trustee | |
| Common StockF1 | holding | — | — | — | 1,203 | I | by trust for grandch |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $21.25 | Aug 20, 2018 | M | 210 | D | — | Dec 18, 2019 | Common Stock | 210 | 307,585 | D |
Explanation of responses
- F1By a trust for the benefit of certain grandchildren of the reporting person, of which the reporting person and/or the spouse of the reporting person is trustee.
- F2The stock option award vests in four equal annual installments, commencing one year after the date of grant.